OSUR Profile
OraSure Technologies, Inc., head quartered in Bethlehem, Pennsylvania, operates as a leading developer, manufacturer, and marketer of oral fluid diagnostic products and specimen collection devices globally. Established in 2000, the company specializes in two core segments: Diagnostics and Molecular Solutions.
Under the Diagnostics segment, OraSure Technologies offers a diverse portfolio of products designed for rapid testing and diagnostics. Key offerings include the InteliSwab COVID-19 rapid test series, which includes professional, prescription, and over-the-counter versions, addressing critical needs in pandemic management. Additionally, the company provides well-known products such as the OraQuick Rapid HIV test, OraQuick In-Home HIV test, and OraQuick HCV rapid antibody test, pivotal in HIV and hepatitis C screening.
In the Molecular Solutions segment, OraSure Technologies excels in genomic products under the Oragene and ORAcollect brands, facilitating efficient collection and stabilization of genetic material for various applications. This segment also encompasses advanced products like the GenoFIND genomics laboratory services and RNA and OMNIgene collection devices crucial for COVID-19 molecular testing.
Beyond diagnostics, the company extends its reach into diverse markets including drug testing systems, immunoassays, and in vitro diagnostic tests. Its comprehensive product offerings cater to a broad spectrum of customers including clinical laboratories, hospitals, clinics, public health organizations, and commercial entities worldwide, ensuring robust support across healthcare and industrial sectors.
|
